Correlation Between GlaxoSmithKline PLC and Wuhan Hvsen

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both GlaxoSmithKline PLC and Wuhan Hvsen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GlaxoSmithKline PLC and Wuhan Hvsen into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GlaxoSmithKline PLC ADR and Wuhan Hvsen Biotechnology, you can compare the effects of market volatilities on GlaxoSmithKline PLC and Wuhan Hvsen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GlaxoSmithKline PLC with a short position of Wuhan Hvsen. Check out your portfolio center. Please also check ongoing floating volatility patterns of GlaxoSmithKline PLC and Wuhan Hvsen.

Diversification Opportunities for GlaxoSmithKline PLC and Wuhan Hvsen

-0.9
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between GlaxoSmithKline and Wuhan is -0.9. Overlapping area represents the amount of risk that can be diversified away by holding GlaxoSmithKline PLC ADR and Wuhan Hvsen Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Wuhan Hvsen Biotechnology and GlaxoSmithKline PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GlaxoSmithKline PLC ADR are associated (or correlated) with Wuhan Hvsen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Wuhan Hvsen Biotechnology has no effect on the direction of GlaxoSmithKline PLC i.e., GlaxoSmithKline PLC and Wuhan Hvsen go up and down completely randomly.

Pair Corralation between GlaxoSmithKline PLC and Wuhan Hvsen

Considering the 90-day investment horizon GlaxoSmithKline PLC ADR is expected to under-perform the Wuhan Hvsen. But the stock apears to be less risky and, when comparing its historical volatility, GlaxoSmithKline PLC ADR is 1.93 times less risky than Wuhan Hvsen. The stock trades about -0.23 of its potential returns per unit of risk. The Wuhan Hvsen Biotechnology is currently generating about 0.24 of returns per unit of risk over similar time horizon. If you would invest  1,106  in Wuhan Hvsen Biotechnology on September 1, 2024 and sell it today you would earn a total of  143.00  from holding Wuhan Hvsen Biotechnology or generate 12.93% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy95.45%
ValuesDaily Returns

GlaxoSmithKline PLC ADR  vs.  Wuhan Hvsen Biotechnology

 Performance 
       Timeline  
GlaxoSmithKline PLC ADR 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days GlaxoSmithKline PLC ADR has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Wuhan Hvsen Biotechnology 

Risk-Adjusted Performance

15 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Wuhan Hvsen Biotechnology are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Wuhan Hvsen sustained solid returns over the last few months and may actually be approaching a breakup point.

GlaxoSmithKline PLC and Wuhan Hvsen Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with GlaxoSmithKline PLC and Wuhan Hvsen

The main advantage of trading using opposite GlaxoSmithKline PLC and Wuhan Hvsen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GlaxoSmithKline PLC position performs unexpectedly, Wuhan Hvsen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Wuhan Hvsen will offset losses from the drop in Wuhan Hvsen's long position.
The idea behind GlaxoSmithKline PLC ADR and Wuhan Hvsen Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.